Who's who · AI in biology and medicine
Isomorphic Labs
Isomorphic Labs, an Alphabet company spun out of DeepMind, uses AI models descended from AlphaFold to design new drugs.
Why it matters: It is the best-funded test of whether AI can make drug discovery faster and cheaper.
Key facts
- Raised $2.1 billion in May 2026 in a round led by Thrive Capital, with Alphabet, GV, MGX, Temasek and the UK Sovereign AI Fund.Source: en.wikipedia.org, as of May 2026
- As of November 2026 its in-house drug programs in oncology and immunology were still preclinical, ahead of planned first-in-human trials.Source: en.wikipedia.org, as of Nov 2026
- Reported in February 2026 that its drug design engine (IsoDDE) doubled AlphaFold 3's performance on a protein-ligand generalization benchmark.Source: en.wikipedia.org, as of Feb 2026
- Max Jaderberg became president in January 2026.Source: en.wikipedia.org, as of Jan 2026
Our latest stories
- Nov 18, 2026 · ConfirmedIsomorphic Labs raises $5 billion, its second billion-dollar round in six months